A brain metastasis is a cancer that has metastasized (spread) to the brain from another location in the body and is therefore considered a secondary brain tumor. The metastasis typically shares a cancer cell type with the original site of the cancer. Metastasis is the most common cause of brain cancer, with primary tumors that originate in the brain being less common. The most common sites of primary cancer which metastasize to the brain are lung, breast, colon, kidney, and skin cancer. Brain metastases can occur in patients months or even years after their original cancer is treated. Brain metastases have a poor prognosis for cure, but modern treatments are allowing patients to live months and sometimes years after the diagnosis.
Because different parts of the brain are responsible for different functions, symptoms vary depending on the site of metastasis within the brain. However, brain metastases should be considered in any cancer patient who presents with neurological or behavioral changes.
Brain metastases can cause a wide variety of symptoms which can also be present in minor, more common conditions. Neurological symptoms are often caused by increased intracranial pressure, with severe cases resulting in coma. The most common neurological symptoms include:
- New onset headaches: headaches occur in roughly half of brain metastasis patients, especially in those with many tumors.
- Paresthesias: patients often present with (hemiparesis), or weakness on only one side of the body, which is often a result of damage to neighboring brain tissue.
- Ataxia: when metastasis occurs to the cerebellum, patients will experience various difficulties with spatial awareness and coordination.
- Seizures: when present, often indicates disease involvement of the cerebral cortex.
- Lung cancer, 48%
- Breast cancer, 15%
- Genitourinary tract cancers, 11%
- Osteosarcoma, 10%
- Melanoma, 9%
- Head and neck cancer, 6%
- Neuroblastoma, 5%
- Gastrointestinal cancers, especially colorectal and pancreatic carcinoma, 3%
- Lymphoma, 1%
Brain imaging (neuroimaging such as CT or MRI) is needed to determine the presence of brain metastases. In particular, contrast-enhanced MRI is the best method of diagnosing brain metastases, though detection is primarily done by CT. Biopsy is often recommended to confirm diagnosis.
The diagnosis of brain metastases typically follows a diagnosis of a systemic cancer. Occasionally, brain metastases will be diagnosed concurrently with a primary tumor or before the primary tumor is found.
Treatment for brain metastases is primarily palliative, with the goals of therapy being reduction of symptoms and prolongation of life. However, in some patients, particularly younger, healthier patients, aggressive therapy consisting of open craniotomy with maximal excision, chemotherapy, and radiosurgical intervention (Gamma Knife therapy) may be attempted.
Symptomatic care should be given to all patients with brain metastases, as they often cause severe, debilitating symptoms. Treatment consists mainly of:
- Corticosteroids – Corticosteroid therapy is essential for all patients with brain metastases, as it prevents development of cerebral edema, as well as treating other neurological symptoms such as headaches, cognitive dysfunction, and emesis. Dexamethasone is the corticosteroid of choice. Although neurological symptoms may improve within 24 to 72 hours of starting corticosteroids, cerebral edema may not improve for up to a week. In addition, patients may experience adverse side effects from these drugs, such as myopathy and opportunistic infections, which can be alleviated by decreasing the dose.
- Anticonvulsants – Anticonvulsants should be used for patients with brain metastases who experience seizures, as there is a risk of status epilepticus and death. Newer generation anticonvulsants including Lamotrigine and Topiramate are recommended due to their relatively limited side effects. It is not recommended to prophylactically give anti-seizure medications when a seizure has not yet been experienced by a patient with brain metastasis.
Radiotherapy plays a critical role in the treatment of brain metastases, and includes whole-brain irradiation, fractionated radiotherapy, and radiosurgery. Whole-brain irradiation is used as a primary treatment method in patients with multiple lesions and is also used alongside surgical resection when patients have single and accessible tumors. However, it often causes severe side effects, including radiation necrosis, dementia, toxic leukoencephalopathy, partial to complete hair loss, nausea, headaches, and otitis media. In children this treatment may cause mental retardation, psychiatric disturbances, and other neuropsychiatric effects.
Brain metastases are often managed surgically if they are accessible. Surgical resection followed by stereotactic radiosurgery or whole-brain irradiation deliver superior survival compared to whole brain irradiation alone. Therefore, in patients with only one metastatic brain lesion and controlled or limited systemic disease, a life expectancy of at least 3 months and a good performance status might be expected.
Chemotherapy is rarely used for the treatment of brain metastases, as chemotherapeutic agents penetrate the blood brain barrier poorly. However, some cancers such as lymphomas, small cell lung carcinomas (SCLC) and breast cancer may be highly chemosensitive and chemotherapy may be used to treat extracranial sites of metastatic disease in these cancers. The effectiveness and safety of using chemotherapy to treat a brain metastasis that came from a SCLC is not clear. An experimental treatment for brain metastases is intrathecal chemotherapy, a technique in which a chemotherapeutic drug is delivered via intralumbar injection into the cerebrospinal fluid. Current research on the treatment of brain metastases includes creating new drug molecules to effectively target the blood-brain barrier and studying the relationship between tumors and various genes. In 2015, the United States FDA approved Alecensa (alectinib) for use in patients with a specific type of non-small cell lung cancer (NSCLC; ALK-positive), a type of cancer which often metastasizes to the brain, whose condition worsened after use or were unable to take another medication, Xalkori (crizotinib).
Immunotherapy, for instance Anti-PD-1 alone or in combination with anti-CTLA-4, appears to be effective in some patients with brain metastases especially when these are asymptomatic, stable and not previously treated 
The prognosis for brain metastases is variable; it depends on the type of primary cancer, the age of the patient, the absence or presence of extracranial metastases, and the number of metastatic sites in the brain. For patients who do not undergo treatment the average survival is between one and two months. However, in some patients, such as those with no extracranial metastases, those who are younger than 65, and those with a single site of metastasis in the brain only, prognosis is much better, with median survival rates of up to 13.5 months. Because brain metastasis can originate from various different primary cancers, the Karnofsky performance score is used for a more specific prognosis.
- Tse, Victor (10 November 2009). "Brain Metastasis". Medscape. Retrieved 13 January 2010.
- "Metastatic Brain Tumors" (PDF). Retrieved 13 August 2017.
- "Tumor Types - National Brain Tumor Society". National Brain Tumor Society. Retrieved 1 August 2017.
- Loeffler, MD, et. al. "Epidemiology, clinical manifestations, and diagnosis of brain metastases". UpToDate. Retrieved 2 August 2017.
- Sawaya, MD, Raymond. "Considerations in the Diagnosis and Management of Brain Metastases". Cancer Network. Retrieved 12 August 2017.
- "Metastatic Brain Tumors". American Association of Neurological Surgeons. Retrieved 3 August 2017.
- "Metastatic Brain Tumors". Memorial Sloan Kettering Cancer Center. Retrieved 3 August 2017.
- Wen, MD, et. al. (1 July 1999). "Management of Brain Metastases". Retrieved 2 August 2017.
- Tse, Victor (10 November 2009). "Brain Metastasis - Morbidity/Mortality". Medscape. Retrieved 13 January 2010.
- "Management of Vasogenic Edema in Patients with Primary and Metastatic Brain Tumors". UpToDate. Retrieved 2 August 2017.
- "Seizures in Patients with Primary and Metastatic Brain Tumors". UpToDate. Retrieved 2 August 2017.
- "Overview of the Treatment of Brain Metastases". UpToDate. Retrieved 2 August 2017.
- "Archived copy" (PDF). Archived from the original (PDF) on 2010-06-13. Retrieved 2010-03-17.
- "Archived copy". Archived from the original on 2010-01-29. Retrieved 2010-01-16.
- Reveiz, Ludovic; Rueda, José-Ramón; Cardona, Andrés Felipe (2012-06-13). "Chemotherapy for brain metastases from small cell lung cancer". The Cochrane Database of Systematic Reviews (6): CD007464. doi:10.1002/14651858.CD007464.pub2. ISSN 1469-493X. PMID 22696370.
- "Definition of intrathecal chemotherapy". Retrieved 2017-08-13.
- El-Habashy, et. al. (May 2014). "Novel treatment strategies for brain tumors and metastases". Pharm Pat Anal. 3: 279–96. doi:10.4155/ppa.14.19. PMC 4465202. PMID 24998288.
- "FDA approves new oral therapy to treat ALK-positive lung cancer". FDA. 11 December 2015. Retrieved 4 August 2017.
- Caponnetto, S; Draghi, A; Borch, TH; Nuti, M; Cortesi, E; Svane, IM; Donia, M (8 March 2018). "Cancer immunotherapy in patients with brain metastases". Cancer immunology, immunotherapy : CII. doi:10.1007/s00262-018-2146-8. PMID 29520474.